Next-IO™ HER3 Therapeutic Monoclonal Antibody Program

About This Program

This program aims to develop HER3 therapeutic monoclonal antibody for colorectal cancer immunotherapy.

Rationale for our program:

These findings indicate an important role for HER3 in CRC progression and metastasis.

HER3

HER3 belongs to the human epidermal growth receptor (EGFR/HER) family and is composed of four members (EGFR / ERBB1 / HER1, ERBB2 / HER2 / Neu, ERBB3 / HER3 and ERBB4 / HER4). HER3 is widely expressed in numerous cells, such as epithelial cells, nerve cells, tumor cells, and mesenchymal cells. HER3 is known to regulate cellular processes such as cell division, cell proliferation, differentiation, angiogenesis, and tumor progression. There is a variety of evidence that HER3 overexpression reduces survival in patients with colorectal cancer, and the mechanism of occurrence is shown in figure 1.

HER3 overexpresses and reduces survival in patients with colorectal cancer. Fig.1 HER3 overexpresses and reduces survival in patients with colorectal cancer. (Gespach, 2012)

Supporting Data

These data support the rationale for the development of the first-in-class human HER3 Abs with an improved therapeutic index for the treatment of colorectal cancer.

Colorectal cancer

Ongoing Clinical Trials

 (Liu, 2019)

Program Plan

We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop HER3 therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.

2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chances to succeed. Look forward to cooperating with you in the near future.

References

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.